Innate Immunity

II-01 AN OESTROGEN RECEPTOR ALPHA FUNCTIONAL MUTANT IS PROTECTIVE IN MURINE LUPUS

Melissa A Cunningham*, Jena Wirth, Jennifer Scott, Jackie Eudaly, Gary S Gilkeson. Division of Rheumatology and Immunology, Medical University of South Carolina; Ralph H. Johnson VA Medical Centre, Charleston, SC USA

Background Systemic lupus erythematosus disproportionately affects females. We previously showed that a functional knockout of oestrogen receptor alpha (ERαKO) resulted in significantly reduced renal disease and increased survival in murine lupus. Dendritic cell (DC) development, which requires both oestrogen (E2) and ERα is impacted, as is activation status and cytokine production. Due to altered hormonal feedback loops, ERαKO mice have hypergonadism and partial endocrine sex reversal. Since elevated E2 and T2 levels may have immunomodulating effects, we studied the phenotype of the lupus-prone ERαKO mouse following ovariectomy (OVX) ± E2 replacement to preserve a physiologic hormonal state. In parallel, we investigated the impact of an ERα complete knockout on lupus disease expression.

Materials and methods ERαKO (functional mutant) and Ex3a (null mutant) strains were backcrossed onto the NZM2410 lupus-prone background. Mice underwent OVX or not, and were E2-repleted or not. Urine and blood were collected at 2 week intervals, and mice were sacrificed at 32 weeks, or earlier if they had high proteinuria or >10% weight loss. Bone marrow was isolated and cultured for 7 days with Flt3L to enrich for DCs. Kidney and spleen single cell suspensions were also isolated. Cells were analysed by flow cytometry.

Results Lupus-prone ERαKO mice were protected from disease expression (no early deaths; no proteinuria at 32 weeks) if they were either unmanipulated or if they were both ovariectomized and E2-repleted (Figure 1). These mice also had fewer inflammatory cDCs (CD11c+ ± CD11b+) from Flt3L-cultured bone marrow, or ex vivo spleen or kidney cells). Interestingly, protection was lost after OVX if no E2 pellet was administered, suggesting that the protective effect requires E2 in the system (despite the lack of a functional ERα). A protective effect was not observed in ERα null lupus-prone mice (Ex3a) when they were similarly OVX’d and E2-repleted.

Conclusions These data suggest that in an oestrogen-replete environment, the presence of the ERα complete knockout on lupus disease expression, partially via impacting DC number and subset, compared to mice expressing full length ERα or a full-length knockout of ERα.

II-02 APPROACHING THE PRECISION THERAPY OF SLE AT THE MIF LOCUS

Rick Bucala*. Department of Medicine/Rheumatology, Pathology, and Epidemiology and Public Health Yale School of Medicine, New Haven CT, USA

Background Gene association studies examining functional polymorphisms in the immunoregulatory cytokine MIF (macrophage inhibitory factor, rs5844572) have shown that SLE patients with end-organ sequelae have an increased frequency of high expression MIF genotypes when compared to patients without end-organ involvement. Plasma MIF levels and TLR-stimulated MIF production also reflect underlying MIF genotype. Among activities relevant to autoimmunity, MIF counter-regulates the immunosuppressive action of glucocorticoids, inhibiting

activation-induced apoptosis, and promotes B cell survival. MIF antagonists show auspicious activity in mouse models of autoimmunity and both anti-MIF (imlalumab) and anti-MIF receptor antibodies (Milatuzumab) have advanced into phase II human clinical testing.

The MIF promoter polymorphism comprises a unique four-nucleotide microsatellite repeat (CATT<sub>7-8</sub>), with higher repeat number producing increased MIF expression. Because there is no information about the transcriptional regulation of these common alleles, we sought to identify the nuclear protein(s) regulating expression at this functional promoter polymorphism.

**Materials and methods** We utilised DNA affinity chromatography and liquid chromatography-mass spectrometry analysis to identify unique nuclear proteins that interact with the −794 CATT<sub>7-8</sub> MIF promoter polymorphism. Functional knockout, ectopic expression, and −794 CATT-length dependent transcriptional assays and tissue microarray studies confirmed findings.

**Results** Proteomic analysis identified the transcription factor MIF, previously implicated in oncogenesis, as a unique −794 CATT<sub>7-8</sub> microsatellite interacting protein. Phosphorylated ICBP90 bound to the MIF promoter in a CATT-length dependent manner and upregulated MIF expression in monocytes, and B and T lymphocytes. Strong correlation was observed between ICBP90 and MIF expression in human inflammatory tissue, with a noteworthy overlap between downstream transcripts regulated by ICBP or MIF.

**Conclusions** ICBP90 regulates MIF transcription at the −794 MIF promoter polymorphism. Pharmacologic targeting of the ICBP90:CATT<sub>7-8</sub> interaction is underway to inhibit MIF promoter overactivity and provide for a structurally-defined, pharmacogenic approach to treatment.

**II-03 PATHOGENESIS OF DIFFUSE ALVEOLAR HAEMORRHAGE (DAH) IN LUPUS**

Hoayang Zhuang, Shuhong Han, Li Lu, Xin Qi, Stepan Shumyak, Lijun Yang, Westley Reeves* University of Florida, Gainesville, FL, USA

II-03 lupus-2016-000179.33

**Background** Diffuse alveolar haemorrhage (DAH) in lupus patients carries a mortality rate of over 50%, C57BL/6 mice with pristane-induced lupus develop DAH closely resembling the human disease. The role of cell death, complement, immunoglobulin, Toll-like receptors, and myeloid cells was examined in pristane-treated mice with DAH.

**Materials and methods** Clinical/pathological and immunological manifestations of pristane-induced lupus in gene-targeted vs. wild type mice were compared with the manifestations in SLE controls. Tissue distribution of pristane was examined histologically and by mass spectrometry. The cell types responsible for disease were examined by in vivo depletion using clodronate liposomes (ClinLip) and anti-neutrophil monoclonal antibodies (GR1). The effect of treatment with the C3b-analogue cobra venom factor (CVF) was examined.

**Results** After peritoneal injection, pristane was detected in the lung by mass spectrometry and oil red staining, and was found to induce cell death, phagocytosis of the dead cells and erythrocytes by alveolar macrophages, consolidation of the alveolar spaces by erythrocytes and inflammatory cells, thickening of the alveolar wall, and extensive cellular proliferation (Ki-67 staining) within the alveolar septa. Small vessel vasculitis characterised by perivascular neutrophils and F4/80<sup>+</sup> macrophages was present. Lung tissue from SLE patients with DAH had a similar appearance. B-cell-deficient (μMT) mice were resistant to the induction of DAH, but susceptibility was restored by infusing IgM. C3-deficient and CD18-deficient mice also were resistant, and DAH could be prevented in wild-type mice by depleting complement with CVF. Induction of DAH was independent of MyD88, TRIF, TNF-α, and type I interferon, but mortality was increased in IL-10-deficient mice. In vivo neutrophil depletion had no effect on susceptibility, whereas treatment with CloLip depleted both resident alveolar macrophages and presumptive bone marrow-derived F4/80<sup>+</sup> macrophages while preventing DAH, suggesting that macrophages are central to DAH pathogenesis.

**Conclusion** Induction of DAH in pristane-lupus is likely to involve opsonization of dead cells in the lung by natural IgM and complement followed by complement receptor 3 (CD11b/CD18) and/or CR4 (CD11c/CD18)-mediated phagocytosis, resulting in lung inflammation. Disease is macrophage-dependent and independent of type I interferon, TNF-α, MyD88, and neutrophils. Complement inhibition and/or macrophage-targeted therapies may be attractive candidates for treating SLE-associated DAH.